Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics


Dicerna Pharmaceuticals, Inc. (DRNA): $26.70

-1.61 (-5.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 318

in industry

DRNA Stock Summary

  • For DRNA, its debt to operating expenses ratio is greater than that reported by only 10.65% of US equities we're observing.
  • With a year-over-year growth in debt of 857.34%, Dicerna Pharmaceuticals Inc's debt growth rate surpasses 98.03% of about US stocks.
  • Revenue growth over the past 12 months for Dicerna Pharmaceuticals Inc comes in at 610.22%, a number that bests 98.53% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to DRNA, based on their financial statements, market capitalization, and price volatility, are SYRS, ZYME, AGIO, CNCE, and AUTL.
  • Visit DRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.dicerna.com.

DRNA Stock Price Chart Interactive Chart >

Price chart for DRNA

DRNA Price/Volume Stats

Current price $26.70 52-week high $29.45
Prev. close $28.31 52-week low $11.75
Day low $25.56 Volume 611,365
Day high $28.24 Avg. volume 770,711
50-day MA $24.40 Dividend yield N/A
200-day MA $22.20 Market Cap 2.00B

Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio


Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.

DRNA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$26.70$26002.21 91748%

Below please find a table outlining a discounted cash flow forecast for DRNA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dicerna Pharmaceuticals Inc ranked in the 100th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 92198.5%; returns of such proportions should be viewed with some skepticism, though. As for the metrics that stood out in our discounted cash flow analysis of Dicerna Pharmaceuticals Inc, consider:

  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • DRNA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 55.7% of tickers in our DCF set.
  • As a business, Dicerna Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%89947%
1%90848%
2%91748%
3%92649%
4%93549%
5%94450%

DVCR, BMRN, THC, NVAX, and VRTX can be thought of as valuation peers to DRNA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


DRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

DRNA Latest Social Stream


Loading social stream, please wait...

View Full DRNA Social Stream

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021 - Stocks News Feed

LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ended Dec. 31, 2020 after market close on Thursday, Feb. 25, 2021. Management will host a conference call at 4:30… Read More »Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

Stocks News Feed | February 18, 2021

Dicerna to Participate in Upcoming Investor Conferences

Dicerna announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

Yahoo | February 18, 2021

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

Dicerna will release its fourth quarter and full year 2020 financial results after market close on Thursday, Feb. 25, 2021.

Yahoo | February 18, 2021

Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space

Dicerna Pharmaceuticals (DRNA) is a small biopharma in the cutting-edge RNAi space. Dicerna has yet to get a product to market, but its close competitor Alnylam has proven the market relevance of RNAi technology, and Dicerna already has some positive Phase 3 results in its lead internal product. In this...

Andy Jones on Seeking Alpha | February 17, 2021

Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by the recurrent kidney and bladder stones. The condition often results in end-stage renal disease. The study will evaluate the safety and efficacy of a single dose of nedosiran and assess the proportion of participants achieving more than a 30% decrease from baseline in 24-hour urinary oxalate on two consecutive visits. The trial is expected to enroll six participants aged six years and above, and results are expected in mid-2021. PHYOX4 participants who respond to treatment with nedosiran and complete the trial are eligible to enroll in the Company's PHYOX3 trial, an ongoing open-label exte...

Yahoo | February 11, 2021

Read More 'DRNA' Stories Here

DRNA Price Returns

1-mo 8.45%
3-mo 8.80%
6-mo 52.14%
1-year 37.56%
3-year 104.44%
5-year 413.46%
YTD 21.20%
2020 0.00%
2019 106.08%
2018 18.38%
2017 213.54%
2016 -75.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8127 seconds.